Central Trust Company’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.77M Buy
19,885
+122
+0.6% +$17.1K 0.05% 213
2025
Q4
$2.43M Buy
19,763
+249
+1% +$30.3K 0.05% 224
2025
Q3
$2.17M Buy
19,514
+35
+0.2% +$3.98K 0.05% 248
2025
Q2
$2.16M Sell
19,479
-400
-2% -$42.6K 0.05% 232
2025
Q1
$2.23M Sell
19,879
-45
-0.2% -$4.64K 0.05% 223
2024
Q4
$1.84M Buy
19,924
+33
+0.2% +$2.97K 0.05% 252
2024
Q3
$1.67M Sell
19,891
-2,566
-11% -$196K 0.04% 257
2024
Q2
$1.54M Sell
22,457
-70
-0.3% -$4.67K 0.04% 265
2024
Q1
$1.65M Sell
22,527
-1,044
-4% -$80.3K 0.04% 258
2023
Q4
$1.91M Sell
23,571
-294
-1% -$22.9K 0.05% 228
2023
Q3
$1.79M Sell
23,865
-212
-0.9% -$16.3K 0.05% 227
2023
Q2
$1.86M Sell
24,077
-2,713
-10% -$216K 0.05% 226
2023
Q1
$2.22M Sell
26,790
-416
-2% -$34.5K 0.07% 210
2022
Q4
$2.34M Sell
27,206
-188
-0.7% -$14.9K 0.07% 207
2022
Q3
$1.69M Buy
27,394
+3,210
+13% +$202K 0.06% 219
2022
Q2
$1.5M Sell
24,184
-9
-0% -$557 0.05% 251
2022
Q1
$1.44M Sell
24,193
-1,326
-5% -$84.8K 0.04% 273
2021
Q4
$1.85M Buy
25,519
+577
+2% +$39.7K 0.05% 255
2021
Q3
$1.74M Buy
24,942
+998
+4% +$70.1K 0.06% 236
2021
Q2
$1.65M Sell
23,944
-1,065
-4% -$71.1K 0.06% 244
2021
Q1
$1.62M Buy
25,009
+540
+2% +$34.8K 0.06% 230
2020
Q4
$1.43M Sell
24,469
-34,306
-58% -$2.07M 0.06% 233
2020
Q3
$3.71M Sell
58,775
-6,370
-10% -$442K 0.17% 114
2020
Q2
$5.01M Buy
65,145
+9,603
+17% +$736K 0.25% 88
2020
Q1
$4.15M Buy
55,542
+25,326
+84% +$1.75M 0.25% 89
2019
Q4
$1.96M Buy
30,216
+2,440
+9% +$159K 0.1% 170
2019
Q3
$1.76M Buy
27,776
+419
+2% +$27.4K 0.1% 173
2019
Q2
$1.81M Sell
27,357
-398
-1% -$26.2K 0.1% 170
2019
Q1
$1.8M Sell
27,755
-1,040
-4% -$69.1K 0.11% 164
2018
Q4
$1.8M Sell
28,795
-274
-0.9% -$19.2K 0.12% 157
2018
Q3
$2.25M Sell
29,069
-25,118
-46% -$1.9M 0.13% 155
2018
Q2
$3.84M Sell
54,187
-5,484
-9% -$387K 0.24% 97
2018
Q1
$4.5M Sell
59,671
-10,893
-15% -$866K 0.29% 85
2017
Q4
$5.05M Sell
70,564
-852
-1% -$64.7K 0.31% 79
2017
Q3
$5.79M Sell
71,416
-6,552
-8% -$501K 0.37% 66
2017
Q2
$5.52M Sell
77,968
-8,939
-10% -$595K 0.36% 72
2017
Q1
$5.9M Sell
86,907
-15,927
-15% -$1.12M 0.39% 69
2016
Q4
$7.36M Sell
102,834
-8,356
-8% -$621K 0.51% 51
2016
Q3
$8.8M Sell
111,190
-4,779
-4% -$388K 0.64% 37
2016
Q2
$9.67M Sell
115,969
-2,279
-2% -$202K 0.72% 32
2016
Q1
$10.9M Sell
118,248
-12,333
-9% -$1.11M 0.86% 26
2015
Q4
$13.2M Sell
130,581
-2,111
-2% -$220K 1.09% 18
2015
Q3
$13M Buy
132,692
+8,426
+7% +$936K 1.13% 15
2015
Q2
$14.5M Buy
124,266
+2,981
+2% +$326K 1.14% 15
2015
Q1
$11.9M Sell
121,285
-11,657
-9% -$1.18M 0.96% 22
2014
Q4
$12.5M Sell
132,942
-1,175
-0.9% -$122K 1.02% 22
2014
Q3
$14.3M Buy
134,117
+2,470
+2% +$242K 1.13% 19
2014
Q2
$10.9M Buy
131,647
+2,974
+2% +$231K 0.86% 24
2014
Q1
$9.12M Buy
128,673
+11,294
+10% +$886K 0.75% 30
2013
Q4
$8.81M Buy
117,379
+2,569
+2% +$179K 0.74% 32
2013
Q3
$7.22M Sell
114,810
-964
-0.8% -$57.6K 0.65% 38
2013
Q2
$5.93M Buy
+115,774
New +$6.03M 0.56% 45

Other funds holding GILD

Central Trust Company's GILD Position: Q1 2026 in Review

Central Trust Company increased its Gilead Sciences (GILD) stake by 0.62% in Q1 2026, buying an estimated $17.1K and bringing the position to 19,885 shares worth $2.77M. The position accounts for 0.05% of the portfolio, ranked #213.

Central Trust Company first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.5M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Central Trust Company held 19,885 shares of Gilead Sciences worth $2.77M as of Q1 2026.
  • Central Trust Company bought 122 Gilead Sciences shares in Q1 2026, an estimated $17.1K.
  • Gilead Sciences made up 0.05% of Central Trust Company's portfolio in Q1 2026, its #213 holding.
  • Central Trust Company first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Central Trust Company's Gilead Sciences position peaked at $14.5M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.